[1]王成斌,王桂云,张青,等.清肺十八味丸联合盐酸氯丙那林治疗老年咳嗽变异性哮喘并发阻塞性肺气肿临床研究*[J].陕西中医,2018,(11):1536-1539.
　Wang Chengbin,Wang Guiyun,Zhang Qing..Clinical effects of Qingfei Shibaweiwan combined with clorprenaline hydrochloride in the treatment of cough variant asthma with obstructive emphysema[J].,2018,(11):1536-1539.
点击复制

清肺十八味丸联合盐酸氯丙那林治疗老年咳嗽变异性哮喘并发阻塞性肺气肿临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2018年11期
页码:
1536-1539
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Clinical effects of Qingfei Shibaweiwan combined with clorprenaline hydrochloride in the treatment of cough variant asthma with obstructive emphysema
文章编号:
10.3969/j.issn.1000-7369.2018.11.014
作者:
王成斌1; 王桂云1;  张青1; 任志超2
1.陕西省铜川矿务局中心医院呼吸内科（铜川 727000）,2.陕西省咸阳市第一人民医院（咸阳712000）
Author(s):
Wang Chengbin;  Wang Guiyun;  Zhang Qing.
Department of Respiratory Medicine,Central Hospital of Tongchuan Mining Bureau (Tongchuan 727000)
关键词:
哮喘肺气肿/中西医结合疗法@清肺十八味丸
Keywords:
AsthmaPulmonary emphysema/integratedChinese traditional and western medicine therapy@Qingfei Shibaweiwan
分类号:
R563.3
文献标志码:
A
摘要:
目的：探讨清肺十八味丸联合盐酸氯丙那林对老年咳嗽变异性哮喘并发阻塞性肺气肿的临床治疗效果。方法：选取194例老年咳嗽变异性哮喘并发阻塞性肺气肿患者作为研究对象，采用随机数字表法将其分为观察组和对照组，每组97例。对照组给予盐酸氯丙那林治疗，而观察组则在此基础上另给予清肺十八味丸。治疗12周后，对两组疗效进行评价。治疗前及治疗12周后，检测两组患者肺功能指标（一氧化碳弥散量、一秒用力呼气容积、呼气峰流速值及呼气高峰流量），血气指标（二氧化碳分压、酸碱度及血氧张力），炎性因子（嗜酸性粒细胞趋化因子、巨噬细胞炎性蛋白-1α、嗜酸性阳离子蛋白及淀粉样蛋白A）。治疗期间，对患者的不良反应进行观察。结果：治疗12周后，观察组总有效率为91.7%，明显高于对照组（77.3%，P<0.05）。治疗12周后，观察组DLCO、FEV1、PEF及PEFR均明显高于对照组（P<0.05），PaCO2、pH及PaO2改善程度均明显优于对照组（P<0.05），且Eotaxin、MIP-1α、ECP及SAA均明显低于对照组（P<0.05）。治疗期间，患者均无严重不良反应，两组不良反应发生率基本一致（P>0.05）。结论：清肺十八味丸联合盐酸氯丙那林可有效改善老年咳嗽变异性哮喘并发阻塞性肺气肿患者肺功能及血气指标，降低患者血清炎性因子含量。
Abstract:
Objective: To explore the clinical effect and safety of Qingfei Shibaweiwan combined with clorprenaline hydrochloride in the treatment of cough variant asthma with obstructive emphysema. Methods: 194 elderly patients of the cough variant asthma with obstructive emphysema were divided into observe group (97 cases) and control group (97 cases). The control group was treated with clorprenaline hydrochloride while the treatment group with Qingfei Shibaweiwan on the base of control group. The treatment lasting 12 weeks in the 2 groups. 12 weeks after the treatment, the clinical effects were compared in patients. Before and 12 weeks after the treatment, the lung function index \[carbon monoxide diffusion capacity (DLCO), forced expiratory volume in one second (FEV1), peak expiratory flow (PEF) and peak expiratory flow rate (PEFR)\], blood gas index \[CO2 partial pressure (PaCO2), acidity (pH) and blood oxygen tension (PaO2)\], inflammatory factor \[eosinophil chemotactic factor (Eotaxin), macrophage inflammatory protein - 1 alpha (MIP-α), eosinophilic cationic protein (ECP) and amyloid A (SAA)\] were detected in the 2 groups. The adverse reactions were observed during the treatment. Results: 12 weeks after the treatment, the total effect rate in observe group was 91.7%（89/97）, significantly higher than control group \[77.3%（75/97）\] (P<0.05). 12 weeks after the treatment, the levels of DLCO, FEV1, PEF and PEFR in observe group were significantly higher than control group (P<0.05), PaCO2, pH and PaO2 were significantly promoted than control group (P<0.05), while Eotaxin, MIP-1α, ECP and SAA were significantly lower than control group (P<0.05). There were no serious adverse actions in 2 groups during the treatment and the rates of adverse actions was similar in the 2 groups （P>0.05）. Conclusions: Qingfei Shibaweiwan with clorprenaline hydrochloride in cough variant asthma with obstructive emphysema has a good effect, can promote the lung function, blood gas index and〖LM〗 inflammatory factor of patients.

参考文献/References:

[1]柯东港. 腰椎间盘突出症发病危险因素及CT影像特点分析[J]. 中国CT和MRI杂志,2016,14(6):133-136.
[2]辛梦玺,庞苗苗,卫凌,等. 经皮椎间孔镜治疗腰椎间盘突出症178例临床观察[J]. 陕西医学杂志,2016,45(10):1329-1330.
[3]孙庆, 张玮, 胡思源,等. 腰痛宁胶囊治疗腰椎间盘突出症(寒湿瘀阻证)的有效性和安全性的随机、盲法、多中心临床对照研究[J]. 中草药, 2016, 47(22):4043-4048.
[4]陈飞, 谷福顺, 王爱国,等. 补阳还五汤加减联合中药湿敷治疗气虚血瘀型腰痹60例临床观察[J]. 湖南中医杂志, 2018, 47 (1):69-71.
[5]贾海鹏, 卢添娇, 上官洁琼,等. 温针灸结合中药热敷治疗腰椎间盘突出症临床观察[J]. 上海针灸杂志, 2016, 35(2)：189-191.
[6]石印玉. 中西医结合骨伤科学 [M]. 北京: 中国中医药出版社, 2007:273.
[7]梁文杰, 方朝义, 沈莉,等. 实验诊断学在现行《中医病证诊断疗效标准》中的应用分析[J]. 河北中医药学报, 2011, 26(2):47-48.
[8]张晶. 关于修订《中药新药临床研究指导原则》的建议[J]. 中药新药与临床药理, 2000, 11(2):67-79.
[9]熊淑英, 杨阳, 余兆仲,等. 中药湿敷配合蜡泥治疗气滞血瘀型腰椎间盘突出症53例[J]. 江西中医药大学学报, 2016, 28(5):62-64.
[10]高志成,尹锦楠,余文惠,等. 钩活术联合红花注射液穴位注射对腰椎间盘突出症患者炎症因子的影响[J]. 陕西中医,2016,37(3):348-350.
[11]何鹏宇,林志义,牟明威. 低温等离子髓核消融术配合穴位埋线治疗腰椎间盘突出症疗效观察[J]. 陕西中医,2015,36(4):438-441.
[12]陈红峰, 吴小涛. NLRP3炎性体、IL-1和IL-18在突出腰椎间盘组织中的表达及意义[J]. 实用临床医药杂志, 2013, 17(9):40-43.
[13]林磊, 李般若, 王青平,等. 突出腰椎间盘组织中PGE2、IL-6的表达与临床病理特征的相关性分析[J]. 临床和实验医学杂志, 2017, 16(19):1948-1951.
[14]谢小梅, 庄健海, 钟树奇,等. 清湿利腰汤对湿热型腰椎间盘突出症患者血清PGE2和5-HT的影响研究[J]. 黑龙江医学, 2018, 42 (2) :140-142.
[15]姚啸生, 孙树椿, 张军,等. 腰痹通胶囊对退变腰椎间盘Ⅱ型胶原含量和TNF- mRNA表达的影响[J]. 中国中医骨伤科杂志, 2014, 22 (7):4-6.
[16]陈子前, 马太平, 刁虹. 中西医结合治疗腰椎间盘突出症患者的临床疗效观察及对血清炎性因子的影响[J]. 世界中医药, 2017, 12(2):299-302.
[17]陈广智. 手法配合中药湿敷治疗腰椎间盘突出症疗效分析[J]. 中国中医骨伤科杂志,2009,17(12):49-50.
[18]李华南, 王金贵, 丛德毓,等. 中医综合治疗方案治疗腰椎间盘突出症多中心随机对照研究[J]. 中医杂志, 2015, 56(21):1840-1844.
[19]阎山林, 陈丽佳, 李正翔,等. 威灵仙的化学成分及生物活性的研究进展[J]. 天津药学, 2016, 28(2):48-52.
[20]陈琪瑶, 张金莲, 刘艳菊,等. 延胡索醋制前后对血瘀模型大鼠血液流变学的影响[J]. 中国医院药学杂志, 2016, 36(11):901-905.
[21]蔡红蝶, 宿树兰, 周卫,等. 乳香属药用植物中乳香酸类化学成分、生物活性及其作用机制研究进展[J]. 中草药, 2016, 47(12):2175-2181.
[21]蒋海峰, 宿树兰, 欧阳臻,等. 乳香、没药提取物及其配伍对血小板聚集与抗凝血酶活性的影响[J]. 中国实验方剂学杂志, 2011, 17 (19):160-165.

备注/Memo

备注/Memo:
*陕西省教育厅自然科学研究项目(2013JK0773)
更新日期/Last Update: 2018-11-30